{
  "pmcid": "11916864",
  "sha256": "a4a51baa1f15243b3947434b7e1e95e45898c2ac225d505b2d3452467cc35b63",
  "timestamp_utc": "2025-11-09T23:22:55.885069+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.622950000000003,
    "reading_ease": 18.053225000000026,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Intravenous Nalbuphine for Attenuation of Pruritus in Postoperative Epidural Morphine Analgesia"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Ninety pregnant ASA II females scheduled for elective cesarean delivery were randomly assigned"
      },
      "Participants": {
        "score": 2,
        "evidence": "Ninety pregnant ASA II females scheduled for elective cesarean delivery"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to receive either nalbuphine (5 μg/kg/hour, Group N5; 10 μg/kg/hour, Group N10) or normal saline (control group)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses the efficacy and safety of intravenous nalbuphine in reducing pruritus and related side effects"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the incidence of pruritus, measured at multiple postoperative intervals"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to patients, clinicians, and outcome assessors"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Ninety participants were randomised: 30 to Group N5, 30 to Group N10, and 30 to the control group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on all participants using an intention-to-treat approach"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Group N10 showed reduced pruritus incidence compared to the control (p < 0.05)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were fewer in nalbuphine groups, with mild severity"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}